Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
ND Trinklein, D Pham, U Schellenberger, B Buelow… - MAbs, 2019 - Taylor & Francis
ABSTRACT T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
activity in humans, but cytokine release-related toxicities have affected their clinical utility …
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents
designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific …
designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific …
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
EJ Smith, K Olson, LJ Haber, B Varghese… - Scientific reports, 2015 - nature.com
Bispecific antibodies, while showing great therapeutic potential, pose formidable challenges
with respect to their assembly, stability, immunogenicity and pharmacodynamics. Here we …
with respect to their assembly, stability, immunogenicity and pharmacodynamics. Here we …
T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity
D Kamakura, R Asano, M Yasunaga - Pharmaceuticals, 2021 - mdpi.com
As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising
antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding …
antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding …
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
LL Sun, D Ellerman, M Mathieu… - Science translational …, 2015 - science.org
Bispecific antibodies and antibody fragments in various formats have been explored as a
means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been …
means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been …
[HTML][HTML] CD20-Tcb (RG6026), a novel “2: 1” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's …
M Hutchings, G Iacoboni, F Morschhauser, F Offner… - Blood, 2018 - Elsevier
Despite advancements in outcomes with the introduction of anti-CD20 monoclonal antibody
therapy, a substantial proportion of B-cell Non-Hodgkin's Lymphoma (B-NHL) patients do …
therapy, a substantial proportion of B-cell Non-Hodgkin's Lymphoma (B-NHL) patients do …
CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory
H Benonisson, I Altıntaş, M Sluijter, S Verploegen… - Molecular cancer …, 2019 - AACR
Immunotherapy of cancer with CD3-targeting bispecific antibodies (CD3 bsAb) is a fast
developing field, and multiple tumor-associated antigens (TAA) are evaluated for …
developing field, and multiple tumor-associated antigens (TAA) are evaluated for …
Development of T-cell engagers selective for cells co-expressing two antigens
DM Dicara, S Bhakta, MA Go, J Ziai, R Firestein… - MAbs, 2022 - Taylor & Francis
ABSTRACT T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments
for hematological cancers. While the utility of TCEs in solid malignancies is being explored …
for hematological cancers. While the utility of TCEs in solid malignancies is being explored …
Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model
D Mandikian, N Takahashi, AA Lo, J Li… - Molecular cancer …, 2018 - AACR
Abstract Anti-HER2/CD3, a T-cell–dependent bispecific antibody (TDB) construct, induces T-
cell–mediated cell death in cancer cells expressing HER2 by cross-linking tumor HER2 with …
cell–mediated cell death in cancer cells expressing HER2 by cross-linking tumor HER2 with …
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
P Fournier, V Schirrmacher - BioDrugs, 2013 - Springer
Monoclonal anti-tumor antibodies (mAbs) that are clinically effective usually recruit, via their
constant fragment (Fc) domain, Fc receptor (FcR)-positive accessory cells of the immune …
constant fragment (Fc) domain, Fc receptor (FcR)-positive accessory cells of the immune …